Skip to main content
All lobbying filings

S-3 GROUP

Lobbying for FRESENIUS KABI · Healthcare/pharmaceutical company

 Filing 2nd Quarter - Report
2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $30,000.00 income · posted Jul 18, 2025

Official filing document

 Lobbying activity 2
Health Issues

Issues related to drug pricing, legislation, biosimilars, patent reform, rebate reform, electronic labeling and FDA Foreign Inspection backlog

Copyright/Patent/Trademark

Issues related to drug pricing, legislation, biosimilars, patent reform, rebate reform, electronic labeling and FDA Foreign Inspection backlog

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem